1. Case report of a pediatric medulloblastoma with concurrent MYC and MYCN subclonal amplification in distinct populations of neoplastic cells.
- Author
-
Minasi S, Gianno F, Bargiacchi L, Barresi V, Miele E, Antonelli M, and Buttarelli FR
- Subjects
- Humans, Male, Biomarkers, Tumor genetics, Biomarkers, Tumor analysis, DNA Methylation, Child, Child, Preschool, Medulloblastoma pathology, Medulloblastoma genetics, Medulloblastoma diagnosis, N-Myc Proto-Oncogene Protein genetics, Gene Amplification, Cerebellar Neoplasms pathology, Cerebellar Neoplasms genetics, Proto-Oncogene Proteins c-myc genetics, In Situ Hybridization, Fluorescence
- Abstract
Medulloblastomas (MDBs) are classified into molecular groups showing peculiar immunohistochemical and genetic features and distinct DNA methylation profile. Group 3 and group 4 MDBs have the worst prognosis; the former is treated with high-risk protocols and features MYC amplification, whereas the latter receives standard-risk protocols and harbors MYCN amplification. Herein, we report a unique case of MDB showing histological and immunohistochemical features consistent with non-SHH/non-WNT classic MDB, with both MYCN (30% of tumor cells) and MYC (5-10% tumor cells) amplification in distinct subclones of neoplastic cells at fluorescence in situ hybridization (FISH), characterized by specific patterns. In spite of MYC amplification in only a small percentage of tumor cells, this case had DNA methylation profile consistent with group 3, emphasizing the importance to test both MYC and MYCN amplifications at a single cell level using highly sensitive methods, such as FISH, for diagnostic and therapeutic purposes., (© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.)
- Published
- 2024
- Full Text
- View/download PDF